NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this publication

☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to:

NIH Guide
Printing & Reproduction Branch
National Institutes of Health
Room B4BN08, Building 31
Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, $300

The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 20, No. 28
July 19, 1991
A PLAN FOR MANAGING THE COST OF BIOMEDICAL RESEARCH

National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

In response to Congressional concerns expressed in the FY 1991 House and Senate Appropriations Reports, the National Institutes of Health (NIH) has prepared a financial management plan entitled, "A Plan for Managing the Cost of Biomedical Research." This document, developed by NIH in consultation with the biomedical research community and the various National Advisory Councils and Boards, outlines the principles on which the plan is based, identifies the specific goals of the plan, and discusses the cost management measures to be taken.
Recently, a number of universities and other nonprofit organizations have requested assistance from the National Institutes of Health (NIH) in providing independent auditors with a schedule of Federal awards by major programs identified by number in the Catalog of Federal Domestic Assistance. The Catalog, published annually by the Office of Management and Budget (OMB), is a Government-wide compendium of Federal programs, projects, services, and activities that provide assistance or benefits to the American public. According to the independent auditors, data showing expenditures by Catalog program codes must be obtained to comply with a related requirement in OMB Circular No. A-133, which is the circular that established requirements for audits of institutions of higher education and other nonprofit organizations. For the Department of Health and Human Services, A-133 has been implemented with amendments revisions to Section 74.62 of Title 45 Code of Federal Regulations Part 74, Administration of Grants (see the FEDERAL REGISTER, Vol. 56, No. 41, Friday, March 1, 1991).

The position of NIH on this issue is as follows. Paragraph 15.c.(1) of A-133 states in describing report contents that "The schedule of Federal awards should identify major programs and show the total expenditures for each program. Individual major programs OTHER THAN RESEARCH AND DEVELOPMENT AND STUDENT AID should be listed as identified in the Catalog of Federal Domestic Assistance." (Emphasis added.) Virtually all of the extramural programs of NIH can be classified under the headings of Research and Development and Student Aid programs. Accordingly, recipients are NOT required to furnish the Catalog number applicable to NIH grants to the auditors engaged to perform A-133 audits. For that reason, the Notice of Grant Award used presently by the NIH does not carry the Catalog number. However, on or about October 1, 1992, we may begin to use a format for the Notice of Grant Award that will identify the number.

If there are any additional questions concerning implementation of OMB Circular No. A-133, please contact:

Mr. Richard Powers
Chief, Financial Advisory Services Branch
Division of Contracts and Grants
National Institutes of Health
Building 31, Room 1B43
Bethesda, MD 20892
Telephone: (301) 496-4401

NOTICES OF AVAILABILITY (RFPs AND RFAs)

RESEARCH SUPPORT FOR THE CLINICAL AND REGULATORY AFFAIRS PROGRAM

RFP AVAILABLE: NIH-NIAID-DMID-92-3

P.T. 34; K.W. 0755015, 0755018

National Institute of Allergy and Infectious Diseases

The Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, is soliciting proposals from organizations having the capabilities and facilities to provide research support for the Clinical and Regulatory Affairs Program with all phases of clinical trial support. This contract support will be provided within a research environment and consortium including clinical investigators, DMID Data Center, DMID Clinical Studies Group, and the Food and Drug Administration (FDA). Specific requirements include the capability to:

NIH GUIDE - Vol. 20, No. 28, July 19, 1991 - Page 2
(2) develop and implement computerized information systems; (3) monitor clinical investigations; and (4) provide general administrative and logistical support to the Clinical and Regulatory Affairs Section, DMID.

The Request for Proposals (RFP) NIH-NIAID-DMID-92-3 will be available on or about July 23, 1991. Responses are due by September 6, 1991. It is anticipated that one cost-plus-fee contract will be awarded with incremental funding over a period of five years.

To receive a copy of this RFP, please supply this office with two self-addressed mailing labels. All inquiries must be in writing and addressed to:

Ms. Sylvia Cunningham
Contracting Officer
Contract Management Branch
National Institute of Allergy and Infectious Diseases
Control Data Building, Room 326P
6003 Executive Boulevard
Bethesda, MD 20892

This advertisement does not commit the Government to award a contract.

EMERGING PATHOGENIC MYCOPLASMAS

RFA AVAILABLE: AI-91-12

P.T. 34; K.W. 0745020, 0715125, 0710070, 0785035, 0710030, 0755010

National Institute of Allergy and Infectious Diseases

Letter of Intent Receipt Date: September 2, 1991
Application Receipt Date: November 8, 1991

PURPOSE

The National Institute of Allergy and Infectious Diseases (NIAID) invites applications for research on the biology and natural history of members of the genus Mycoplasma that have recently been recognized as potential human pathogens.

ELIGIBILITY REQUIREMENTS

Domestic universities, medical colleges, hospitals, and other public or private research institutions, including State and local government units, are eligible. Awards to foreign institutions under this request will be made only for research of unusually high merit, need and promise, and in accordance with Public Health Service policy governing such awards. Applications from minority investigators and women are encouraged.

BACKGROUND

Mycoplasmas are known to cause a wide variety of diseases in humans and domesticated animals. Mycoplasma spp. are the cause of mastitis in cattle, sheep, and goats, upper and lower respiratory tract infections and arthritis in swine, and chronic respiratory disease in fowl. In humans, Mycoplasma pneumoniae is the etiologic agent of primary atypical pneumonia.

A great deal of interest and controversy has been generated by reports of a species of mycoplasma that is associated with cases of AIDS and with a small number of fatal infections in HIV-negative individuals. The organisms associated with these cases recently have been determined to be strains of Mycoplasma fermentans. Previously regarded as a commensal organism, M. fermentans has been isolated infrequently from humans. However, recent reports from several laboratories indicate that this organism is detectable in HIV-positive individuals at a much higher frequency than in HIV-negative individuals. Preliminary reports indicate that the same may be true for other species of Mycoplasma, particularly Mycoplasma genitalium. Although there is compelling evidence that at least some strains of M. fermentans and M. genitalium are human pathogens, the critical host and microbiologic factors that define the pathogenic relationship require further investigation. Delineation of these factors will lead to effective approaches in diagnosis, treatment, prevention, and control.
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000", a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Emerging Pathogenic Mycoplasmas, is related to the priority area of HIV infection. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, D.C. 20402-9325 (telephone 202-783-3238).

RESEARCH GOALS AND SCOPE

The goal of this RFA is to stimulate innovative basic and/or clinical research on relevant aspects of the biology and natural history of M. fermentans and on host responses that influence pathogenesis of human disease. Of particular interest are studies on pathogenesis aimed at characterizing interaction of mycoplasmas with host cells and with the host defense system, particularly studies aimed at characterizing any immunosuppressive activity of M. fermentans. A serious impediment to studies on M. fermentans is the problem of recovery from infected animals or patients. Therefore, studies focused upon growth of these organisms with particular emphasis on physiologic transitions that occur in response to changes in environment, such as from host to tissue culture or to synthetic culture, are also of interest. Applicants are encouraged, depending upon their expertise, to address one or more of the following research areas:

- Epidemiologic studies on M. fermentans infection in humans, especially HIV-positive individuals, including transmission and natural history studies;
- Studies of the biology of M. fermentans to include: physiology, biochemistry, genetics, and structure and function of surface constituents;
- Studies focused upon non-specific inflammatory and specific immune responses to infection by M. fermentans;
- Studies focused upon mechanisms of virulence or colonization that are important in the pathogenic activities of M. fermentans;
- Development of improved culture techniques for more efficient recovery of isolates from patients;
- Development of a sensitive and specific assay for detection of the presence of M. fermentans in the host; and
- Development of animal models for in vivo study of pathogenesis and host response.

One or several of the above areas may be included in an application. Applicants may also consider other avenues of investigation that would be consistent with the goals of this RFA. Although the primary focus of this RFA is upon M. fermentans, other species of Mycoplasma, particularly M. genitalium, may be considered if the objectives of the research are consistent with the objectives of this RFA.

MECHANISM OF SUPPORT

The support mechanism for this program will be the traditional individual research grant (R01). Responsibility for planning, direction, and execution of the proposed project will be solely that of the applicant.

NIAID anticipates making five to eight awards, totaling $1,000,000, as a result of this solicitation. However, the number of awards made will be dependent upon receipt of a sufficient number of applications of high scientific merit and upon the availability of funds. If appropriate, collaboration with other investigators or institutions is encouraged. It is expected that each award for the first year will be in the range of $125,000 to $225,000 in total (direct plus indirect) costs, although individual awards may be slightly higher or lower. Awards will be made for a project period of up to five years. (Awards to foreign institutions will be limited to three years and will not include indirect costs.) The earliest possible award date is July 1, 1992.

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES
For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women and minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review.

APPLICATION AND REVIEW PROCEDURES

The research grant application form PHS 398 (revised 10/88) must be used in applying for these grants. These forms are available at most institutional business offices and from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Room 449, Westwood Building, 5333 Westbard Avenue, Bethesda, MD 20892.

Applications must be received by November 8, 1991. Applications received after the above date will be returned without review. If the application submitted in response to this RFA is substantially similar to a research grant application already submitted to the NIH for review, but has not yet been reviewed, the applicant will be asked to withdraw either the pending application or the new one. Simultaneous submission of identical applications will not be allowed, nor will essentially identical applications be reviewed by different review committees. Therefore, an application cannot be submitted in response to this RFA that is essentially identical to one that has already been reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique.

Applications will be received by the NIH Division of Research Grants (DRG) and assigned to NIAID. Applications will be reviewed by NIAID staff to determine administrative and programmatic responsiveness to this RFA; those judged to be non-responsive will be returned to the applicant without review. By mutual agreement between the applicant and NIAID staff, a non-responsive application may be processed as an unsolicited R01 application for the next review cycle. Those applications considered responsive to the RFA may be subjected to a triage review by an NIAID peer review group, before or during the initial review committee meeting, to determine their scientific merit relative to the other applications in response to the RFA. The NIAID will withdraw from competition those applications judged by the triage peer review group to be noncompetitive for award and will notify the applicant Principal Investigator and the institutional business official.

Those applications judged to be responsive to this solicitation will be reviewed for scientific and technical merit by a review committee convened by the Division of Extramural Activities, NIAID, during March 1992. The second level of review will be provided by the National Advisory Allergy and Infectious Diseases Council in May 1992.

Letter of Intent: Prospective applicants are asked to submit a letter of intent by September 2, 1991. This letter should include the name of the institution any other participating institutions, the Principal Investigator and other key investigators, and a descriptive title. Such a letter of intent is not binding and will not enter into the review of any application subsequently submitted, nor is it a necessary requirement for application. Letters of intent are requested solely for review planning purposes. NIAID staff will not provide responses to such letters. Letters of intent are to be sent to:

Dr. Olivia Preble
Chief, Microbiology and Immunology Review Section
Program and Project Review Branch
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Westwood Building, Room 3A10
Bethesda, MD 20892
Telephone: (301) 496-8208

The full RFA may be obtained from:

Dr. Robert L. Quackenbush
Chief, Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 738
Bethesda, MD 20892
Telephone: (301) 496-7728

NIH GUIDE - Vol. 20, No. 28, July 19, 1991 - Page 5
For fiscal and administrative matters, contact:

Mr. Todd Ball  
Chief, Microbiology and Infectious Diseases Grants Management Section  
GMB, DEA  
National Institute of Allergy and Infectious Diseases  
Westwood Building, Room 718  
Bethesda, MD 20892  
Telephone: (301) 496-7075

This program is described in the Catalog of Federal Domestic Assistance No. 93.856 - Microbiology and Infectious Disease Research. Grants are awarded under the authority of the Public Health Service Act, Title IV, Section 301 as amended, Public Law 78-410; Public Law 97-219; Public Law 99-158; Public Law 99-500; and Report 99-711 to accompany HR 5233 and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

ONGOING PROGRAM ANNOUNCEMENTS

CLINICAL INVESTIGATOR DEVELOPMENT AWARD

PA: PA-91-78

P.T. 34; K.W. 0715032, 0715040, 0715165, 0750010, 0785035

National Heart, Lung, and Blood Institute

I. PURPOSE AND ELIGIBILITY

The National Heart, Lung, and Blood Institute (NHLBI) announces the availability of the CIDA. The CIDA includes features of and replaces the Physician Scientist Award and the Clinical Investigator Award. The CIDA is intended to allow greater flexibility in developing a program suited to the experience and capabilities of the candidate. The objectives of the NHLBI in supporting the CIDA are to:

- encourage research-oriented physicians to develop independent research skills and gain experience in advanced methods and experimental approaches in the basic and applied sciences relevant to heart, blood vessel, lung, blood diseases, and transfusion medicine;

- increase the pool of physician investigators who can use advanced technologies to address the major problems in heart, blood vessel, lung, and blood diseases, and transfusion medicine.

The CIDA provides research development opportunities for physicians with varying levels of research experience, who are committed to developing into independent investigators. This award will enable candidates holding health professional doctoral degrees, such as the M.D., D.O., D.V.M., or equivalent degree, to undertake three to five years of special study and supervised research with the goal of developing into independent investigators. For individuals with M.D. or D.O. degrees, it is required that at least two years have elapsed since the granting of the doctoral degree at the time an award is made. Individuals desiring subspecialty training may wish to complete their clinical fellowship training before starting the CIDA or, alternatively, by interrupting the award to complete clinical training, they may integrate their clinical fellowship training with the research training and development provided by the CIDA(1). Applications may be accepted from those who hold a Ph.D. degree in addition to a health professional degree if special circumstances can be shown, such as the Ph.D. degree was earned in an unrelated field or an intervening period of clinical training or other non-research activities occurring since completion of the Ph.D. degree. Such applications will be considered on a case-by-case basis.

(1) The CIDA may not be used to support clinical training or duties, but the award may be interrupted or suspended to allow for the completion or continuation of clinical training followed by resumption of CIDA support for the completion of the research development program.

The award is intended to serve research career development needs of clinically trained individuals by providing them with research opportunities appropriate for their scholastic background, previous research experience, and past achievements. Physicians who have little research experience and need guided
course work and supervised laboratory experiences are eligible to apply. Individuals who do not require additional courses but who need an intensive research experience under the guidance of an established scientist are also eligible to apply, as are trainees on institutional research training grants or individual postdoctoral fellowships from the NIH or other organizations. Women and minorities are encouraged to apply. Current or past Principal Investigators of an NIH grant or its equivalent are not eligible. In general, applicants for the award should have no fewer than 2 years of postdoctoral experience.

All programs should be carefully tailored to meet individual needs and must include a sponsor(s) who is competent to provide appropriate research guidance. The CIDA can be integrated with the requirements for clinical training, and differing approaches for doing so may be proposed. In order to allow for the integration of research training with clinical training, a CIDA development plan may provide for an interruption in grant support and the research development program to allow for additional clinical training. For example, individuals with limited clinical and research training may propose a program encompassing a one- to two-year break in the program to allow for completion of subspecialty training, followed by continuation of the research development program. The period of interruption or leave would be without award support and would not reduce the total number of months of support for which an individual is eligible. Other more experienced candidates, may simply propose to devote a limited effort (20 percent or less) to clinical duties that relate to the overall program during the course of the CIDA.

At the time of application, individuals must be either citizens or noncitizen nationals of the United States or have been lawfully admitted to the United States for permanent residence. An individual lawfully admitted for permanent residence must submit, with the application, a notarized statement indicating possession of the Alien Registration Receipt Card (I-151 or I-551). Individuals on temporary or student visas are not eligible.

II. PROVISIONS OF THE AWARD

1. Environment

Applications will be accepted from domestic universities, medical schools, or comparable institutions with strong, well-established research and research training programs, adequate numbers of accomplished faculty in the basic and clinical sciences, and a commitment and capability to provide guidance to clinically trained individuals during their development of independent research careers. Evidence of institutional commitment to the candidate's research and development must be provided in a plan that identifies personnel and other resources to be devoted to that candidate.

2. Program

Candidates must be nominated by an institution on the basis of qualifications, interests, accomplishments, motivation, and potential for performing quality research. The candidate's academic background, previous experience, and career goals should determine both the necessary length and the kind of program that is appropriate. The candidate and sponsor are jointly responsible for the preparation of the research development plan.

All candidates must provide a full description of the research and career development plan for the period of the award. The proposed plan must include hands-on research experience, with either a clinical or a basic focus, for the entire three- to five-year period. Programs may include studies and research endeavors leading to either a Masters degree, such as an M.P.H. degree, or a Ph.D. degree, if the objective is the development of the candidate into an independent investigator. Awardees, in conjunction with their sponsor(s), are required to submit a detailed annual progress report.

Candidate with Minimal Research Experience

If the candidate has minimal research experience, the individual's program should be designed to start with a creative and detailed scientific learning experience and progress to an intensive research activity under the guidance of a qualified sponsor(s). The first year or two of the program may incorporate any needed course work, an initial hands-on research experience, seminars, and other educational experiences necessary to prepare the candidate for the subsequent research program. This initial phase of the program may resemble and replace a traditional postdoctoral research training program. The remainder of the development plan must include an intensive, fully-described research program and projects that can be reasonably completed within the planned period. During this latter phase, the program must provide
for progressive development of the individual into an independent investigator.

Candidate with Prior Research Experience

If the candidate has already acquired some research experience, as might be obtained through a research fellowship, but needs further development under the guidance of an established scientific sponsor(s), the candidate may propose to spend three to five years solely in an advanced research experience focusing on a specific research project.

Such a candidate, however, may take additional courses or engage in special instruction in research techniques in other laboratories for a reasonable time if needed. Individuals with significant research experience in the proposed field of study may not be eligible for this award and should consider applying instead for independent research support.

3. Sponsor

Each candidate must identify a sponsor who is an accomplished investigator in the research area proposed and has experience in developing independent investigators. The sponsor must provide a written plan for the development of the candidate and provide guidance during the preparation of the research project. A secondary sponsor may also be proposed, but the primary sponsor must continue to be involved throughout the award period. In some cases, candidates may choose to have both a basic research sponsor and a clinical research sponsor.

4. Advisory Committee

A committee composed of the candidate's sponsor(s) and two or three other senior faculty members must be identified. This advisory committee must meet with the candidate to review the research development plan and research project, to evaluate the awardee's progress, and to provide guidance for scientific career development. The committee report must be included in the annual progress report submitted with the noncompeting continuation application.

5. Duration and Effort

The award is granted for three to five years depending upon the needs of the candidate and the evaluation by the initial review group and the National Heart, Lung and Blood Advisory Council. It is non-renewable and not transferable, but substitution of another sponsor and/or a change of institution may be permitted with the prior approval of the NHLBI. All funds must be used on behalf of the original candidate. A minimum of 80 percent effort must be devoted to the research program. The remainder may be devoted to other clinical and teaching pursuits that are consonant with the program goals, i.e., the candidate's development into an independent biomedical scientist or the maintenance of the teaching and clinical skills needed for an academic research career.

The candidate must have a "full-time" appointment at the applicant institution. In general, candidates who have Veterans Administration (VA) appointments may not consider part of the VA effort toward satisfying the "full-time" requirement at the applicant institution. Although exceptional cases may be approved, any request to count a part of the VA effort toward satisfaction of the "full-time" research effort requirement of the award must be strongly justified. All such exceptional cases must otherwise meet the intent of the guidelines. Under no circumstances may the CIDA be used to reimburse part of the VA Federal salary. It is permissible for part or all of the research program to be conducted in a VA laboratory, if, for example, the mentor has a VA appointment, but the above conditions must be satisfied by the CIDA candidate.

6. Allowable Costs

a. Salary -- Individual compensation is based on the institution's salary scale for individuals at an equivalent experience level. Funding from this award for salary may not exceed $50,000 per year plus commensurate fringe benefits for essentially full-time with at least 80 percent effort devoted to the research program. NIH policy permits supplementation of salary from non-Federal sources.

b. Research and Development Support -- A maximum of $15,000 per year may be requested for research project requirements and related support, e.g., technical personnel costs, supplies, equipment, candidate travel, telephone
charges, publication costs, and tuition for necessary courses. All expenses must be justified in the application.

c. Indirect Costs -- Reimbursement of actual indirect costs at a rate up to, but not exceeding, eight percent of the total allowable direct costs of each award, exclusive of tuition, fees, and expenditures for equipment.

7. Concurrent Applications

CIDA applications may not be submitted or awarded concurrently with other NIH applications, such as the Research Career Development Award, FIRST Award, Academic Award, or Research Project Grant.

8. Subsequent Applications for NIH Research Support

During the later years of the CIDA, incumbents are encouraged to apply for independent research support, such as the FIRST Award or other research project grants. CIDA recipients who are successful in obtaining NIH research grant support may elect either to terminate the CIDA immediately and begin the research grant, or alternatively, to terminate the CIDA on its anniversary date and begin the research grant at that time. Since concurrent support is not permitted, CIDA recipients who apply for subsequent research grant support are encouraged to include salary and all other research needs in the research grant application.

III. EVALUATION

Awardees will be encouraged to provide a detailed report to the National Institutes of Health annually for a period of five years subsequent to completion of the award about academic status attained, publication authorship, and research grants or contracts received.

IV. MECHANISM OF SUPPORT

The mechanism of support for this activity will be the career development grant (K08). The award of grants pursuant to this announcement is contingent upon availability of appropriated funds.

V. REVIEW METHODS AND CRITERIA

Applications received in response to this announcement will be reviewed in accordance with the usual NIH peer review procedures. They will be reviewed initially for the potential to develop the candidate's research career and for scientific and technical merit by an NHLBI review group composed mostly of non-Federal scientific consultants (initial review group). Following the initial review, the applications will be evaluated by the National Heart, Lung, and Blood Advisory Council.

The criteria for initial review of applications include:

1. Candidate -- Candidate's overall competence as demonstrated by academic record and clinical performance, potential for a career in independent research, and commitment or interest in pursuing an academic research career.

2. Sponsor(s) -- The sponsor's accomplishments in the scientific research area(s) proposed, experience and track record in training investigators, and commitment for the duration of a candidate's research development. A curriculum vitae with relevant publications and a list of current and pending research support must be included for all sponsors. Sponsors must also include a list of current and past research trainees (not more than the last 10 years) with information on their current positions.

3. Environment -- The institution's ability to provide adequate facilities, resources, and opportunities necessary for the candidate's training; the institutional commitment to the candidate; the quality and extent of interaction of the faculty in the basic and clinical sciences; and the quality of the institution's research and research training programs.

4. Career Development Plan -- The adequacy of the research career development plan, based on the candidate's past research experience, training, and career goals.

5. Research Project -- Scientific merit of the proposed research project and its appropriateness as a vehicle for developing the candidate's research skills.

6. Advisory Committee -- Appropriateness of the advisory committee to meet the research career development needs of the candidate.
VI. APPLICATION PROCEDURES

Applications must be submitted on the research grant application form PHS 398 (rev. 10/88). If not available at the applicant institutional office of sponsored programs, the form may be requested from:

Office of Grants Inquiries
Division of Research Grants
National Institutes of Health
Westwood Building, Room 449
Bethesda, MD 20892
Telephone: (301) 496-7441

The original application along with five copies must be mailed to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892

One copy must be mailed to:

NHLBI Scientific Review Administrator
NHLBI Research Training Review Committee
Review Branch
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 550
Bethesda, MD 20892

Supplemental Instructions for completing and submitting the application are available from the NHLBI contacts listed below.

Receipt dates of applications by the Division of Research Grants, NIH, are as follows:

<table>
<thead>
<tr>
<th>Application Dates</th>
<th>NHLBI Advisory Council Review Dates</th>
<th>Earliest Starting Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 1</td>
<td>October</td>
<td>December 1</td>
</tr>
<tr>
<td>June 1</td>
<td>February</td>
<td>April 1</td>
</tr>
<tr>
<td>October 1</td>
<td>May</td>
<td>July 1</td>
</tr>
</tbody>
</table>

VII. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE CONTACTS

Division of Blood Diseases and Resources -- The Division supports research career development in basic and clinical investigation. Candidates are encouraged to acquire expertise in disciplines such as biochemistry, physiology, genetics, cellular and molecular biology, biophysics, endocrinology, immunology, and also statistics, epidemiology, and research design as related to a broad spectrum of topics in blood diseases and transfusion medicine. Such topics include thrombosis and thromboembolic disorders, hemostasis, red blood cell diseases and the hemoglobinopathies, hematopoiesis, sickle cell disease, blood resources, transfusion therapy and transfusion-transmitted diseases, graft-versus-host disease, and marrow transplantation.

Fann Harding, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
National Institutes of Health
Federal Building, Room 5A08
Bethesda, MD 20892
Telephone: (301) 496-1817

Division of Heart and Vascular Diseases -- The Division supports career development in basic science and clinical investigation. Research training may be in fundamental studies of basic processes and functions; behavioral studies, including risk factor modification; genetics (including studies of populations); and primary or secondary prevention or clinical investigations directed toward increasing our knowledge and understanding of cardiovascular disease. Areas of scientific interest to the Division include hypertension, arteriosclerosis, coronary heart disease, cardiovascular aspects of diabetes, arrhythmias, heart failure and shock, cerebrovascular disease, peripheral vascular disease, congenital and rheumatic heart diseases, cardiomyopathies and infections of the heart, circulatory assistance, and cardiovascular devices and technology.

NIH GUIDE - Vol. 20, No. 28, July 19, 1991 - Page 10
Division of Lung Diseases -- The Division supports research career development in basic science and clinical investigation. Research training in the disciplines of cellular and molecular biology, biochemistry, physiology, embryology, immunology, epidemiology, and behavioral medicine are encouraged. Areas of scientific interest to the Division include: cellular and developmental biology, pediatric pulmonary diseases, emphysema, asthma, fibrotic and immunologic lung diseases, acute respiratory failure, pulmonary vascular diseases, pulmonary aspects of AIDS, and respiratory disorders of sleep.

Mary Reilly, M.S.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 640
Bethesda, MD 20892
Telephone: (301) 496-7668

The programs of the National Heart, Lung, and Blood Institute are identified in the Catalog of Federal Domestic Assistance, numbers 93.837, 93.838, and 93.839. Awards will be under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended, 42 Part 241). The regulations (Code of Federal Regulations, 42 Part 52 and 45 Part 74) and policies that govern the research grant programs of the National Institutes of Health will prevail. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or to Health Systems Agency review.

ERRATA

COOPERATIVE AGREEMENTS AS THE AWARD INSTRUMENT FOR CERTAIN NHLBI CLINICAL TRIALS AND LARGE-SCALE EPIDEMIOLOGICAL STUDIES
P.T. 34; K.W. 0755015, 0785055, 0715040
National Heart, Lung, and Blood Institute

This notice was published in the NIH Guide for Grants and Contracts on July 12, 1991, Vol. 20, No. 27. The code numbers for the 'P.T.' line were inadvertently omitted and are included in this erratum.

PROGRAM PROJECTS ON NEW METHODS OF IMMUNE INTERVENTION
RFA AVAILABLE: AI-91-11
P.T. 34; K.W. 0710070, 0745045, 0715015, 0715110, 0715026
National Institute of Allergy and Infectious Diseases

This notice was published in the NIH Guide for Grants and Contracts on July 12, 1991, Vol. 20, No. 27. The code numbers for the 'P.T.' line were inadvertently omitted and are included in this erratum.

FOGARTY INTERNATIONAL RESEARCH COLLABORATION AWARD
PA: PA-91-77
P.T. 34, 48; K.W. 0710030
Fogarty International Center

This notice was published in the NIH Guide for Grants and Contracts on July 12, 1991, Vol. 20, No. 27. The code numbers for the 'P.T.' line were inadvertently omitted and are included in this erratum.